INS and type 2 diabetes mellitus: Glucokinase activator (GKA), dorzagliatin, rough allosteric modulation, fully activates GK by stabilizing its active conformation, thereby improving β-cell function, reducing insulin resistance and remodeling glycemic homeostasis in patients with T2DM [73,74].